SCHEMBL3854562

SCHEMBL3854562

CNC(Cc1cn(Cc2cccc(C)c2)c2ccccc12)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
LMNA P02545 2/20 0.50
ICMT O60725 2/20 0.50
MAPT P10636 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49
KMT2A Q03164 1/20 0.49
ADAM17 P78536 8/20 0.49
HDAC1 Q13547 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
CHRNB2 P17787 1/20 0.45
CHRNA7 P36544 1/20 0.45
CHRNA4 P43681 1/20 0.45
TP53 P04637 1/20 0.45
MMP2 P08253 1/20 0.44
MMP13 P45452 1/20 0.44
MMP14 P50281 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3854566 1.00 ALDH1A1 (0.50) ALDH1A1LMNAICMTMAPTNPSR1
SCHEMBL3855615 0.92 ALDH1A1 (0.53) ALDH1A1LMNAICMTMAPTNPSR1
SCHEMBL3855607 0.92 ALDH1A1 (0.53) ALDH1A1LMNAICMTMAPTNPSR1
SCHEMBL3852590 0.89 ADAM17 (0.49) ALDH1A1LMNAICMTMAPTNPSR1
SCHEMBL3852584 0.89 ADAM17 (0.49) ALDH1A1LMNAICMTMAPTNPSR1
SCHEMBL3849468 0.88 ADAM17 (0.59) MAPTKMT2AADAM17HDAC1HDAC8
SCHEMBL3849476 0.88 ADAM17 (0.59) MAPTKMT2AADAM17HDAC1HDAC8
SCHEMBL3849402 0.86 ADAM17 (0.63) ALDH1A1LMNAICMTKMT2AADAM17
SCHEMBL3849409 0.86 ADAM17 (0.63) ALDH1A1LMNAICMTKMT2AADAM17
SCHEMBL22909611 0.83 HDAC6 (0.54) KMT2AADAM17HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7576222-B2 N-{[4-(but-2-ynyloxy)phenyl]sulfonyl}-1-(2-fluorobenzyl)-5-methoxy-2-methyltryptophan; for treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, ulcerative colitis, or Crohn's disease WYETH (US) 2009-08-18 US disclosed
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase WYETH (US) 2006-07-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160884-A1 Alkynyl-containing tryptophan derivative inhibitors of tace/matrix metalloproteinase ADAM17, TPSAB1, ADAM10 ALDH1A1 740/4885LMNA 991/4885ICMT 3225/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.